Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

BioCryst Pharmaceuticals Inc BCRX

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.


NDAQ:BCRX - Post by User

Comment by mevanion Jan 22, 2021 11:41am
172 Views
Post# 32359587

RE:RE:This is a long term hold for me

RE:RE:This is a long term hold for meI have been accumulatig  BCRX since the $3's  up to and including the $9's  more recently.  Seems to have worked out for me.  So many catalysts and two drugs already on the market.  Sales will only increase from here.   We had Japan approval today as well.   Shorts have hammered this stock all the way up.    As soon as the institutions stop lending their shares out, we may see a short squeeze once Factor D results are dropped.   This is getting very interesting.  
<< Previous
Bullboard Posts
Next >>